Combatting Opioid Use Disorder with Medication-Assisted Therapy: Strategies for Success
Earn CME for related activities: https://www.naccme.com/cme
Dr. Arwen Podesta reviews current evidence-based guidelines and best practices for medication-assisted therapy (MAT) for opioid use disorder (OUD), examines the barriers to successful implementation, and outlines strategies to better navigate specific requirements and barriers for treatment in specialized settings.
© 2019 NACCME, an HMP Company
Видео Combatting Opioid Use Disorder with Medication-Assisted Therapy: Strategies for Success канала HMP Education
Dr. Arwen Podesta reviews current evidence-based guidelines and best practices for medication-assisted therapy (MAT) for opioid use disorder (OUD), examines the barriers to successful implementation, and outlines strategies to better navigate specific requirements and barriers for treatment in specialized settings.
© 2019 NACCME, an HMP Company
Видео Combatting Opioid Use Disorder with Medication-Assisted Therapy: Strategies for Success канала HMP Education
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Practical Application of Negative Pressure Wound Therapy with Instillation
The Patient Centered IBD Medical Home: Will This be the Future of IBD Healthcare Delivery?
Key Insights: Updates in Colorectal Cancer
Complex Clinical Cases: GI Bleeds
Key Insights: Novel Targets for IBD Therapy - Is This the Final Frontier?
Segment 2: Risk Assessment in Prostate Cancer
Mechanisms of Angiogenesis Inhibitors in Metastatic Colorectal Cancer
Virtual Patient Case: Carcinoid Syndrome #1 - Initial Presentation
Challenges Facing Medical Oncology Practice in the Next Decade
New agents/strategies on the horizon in bile duct cancer
What Determines “Quality” for Endoscopy Reporting in IBD Patients?
Optimizing Lumbar Discectomy: Closing Holes in the Disc
Expert Perspectives: MPN and MDS
Molecular Alterations and New Drugs in Bile Duct Cancer
Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors
Major Depressive Disorder: Leveraging the PCMH Model to Improve Patient-Centered Management
Multiple Myeloma Update: Maintenance Therapy
The Current Landscape of Biosimilars in IBD
Can We Increase the Immunogenicity in MSS CRC?
Optimizing Biological Therapies in the Modern Era
Key Insights in Chronic Lymphocytic Leukemia